Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s128. https://doi.org/10.25251/skin.1.supp.127